Lyell Immunopharma, Inc.
LYELHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeLyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. At a $331.6M market cap, Lyell Immunopharma, Inc. ranks as a small-cap company within healthcare. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorec.
Market Cap
$331.6M
Beta
-0.05
P/E (TTM)
—
P/E (Fwd)
-2.14
EPS (TTM)
$-12.69
EPS (Fwd)
$-6.32
ROE
-93.3%
ROA
-34.2%
Cash
$204.1M
Total Debt
$46.6M
Free CF
-$72.8M
52W Change
10.0%
Annual Financials
Cash vs Debt
Where LYEL stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, LYEL finished 20.60% below its 150-day moving average ($18.30) and 28.56% below its 200-day moving average ($20.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LYEL overbought or oversold?
At the September 2, 2026 close, LYEL's RSI(14) was 52.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Lyell Immunopharma, Inc. holds $204.1M in cash against $46.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$72.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -93.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $84.7M (2022) to $36K (2025), a 100% decline worth watching.
With a beta below 0.7, Lyell Immunopharma, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, LYEL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing LYEL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.